Olivia C./LinkedIn
Mar 26, 2026, 17:14
Olivia C.: Pfizer’s mRNA BNT162b2 Vaccine Does Not Induce High Levels of Inflammation
Olivia C., Business Development Manager at Pfizer, shared a post on LinkedIn:
“Precise data on changes in hematological parameters in vaccinated patients are essential to accurately reflect advancements in medical technology.
Infections can cause significant changes in certain hematological parameters and exacerbate inflammatory responses, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and ferritin levels.
In contrast, Pfizer’s mRNA-based BNT162b2 vaccine does not induce high levels of inflammation.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments
-
Nov 16, 2026, 12:44Stefan Prendić: How Intronic Variants Affect Rh Blood Group Antigen Expression